Drugs / PLD
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03353831 Background | Sep 2018 → Mar 2025 | ovarian carcinoma | AGO Research GmbH | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLD | “Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28” NCT03353831 ↗ |
| Route | Intravenous | “Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28” NCT03353831 ↗ |